The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Coherus BioSciences Inc

Nasdaq: CHRS
Last

(U.S.) $19.20

Today's change-0.70 -3.52%
Updated April 28 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Coherus BioSciences Inc

Nasdaq: CHRS
Last

(U.S.) $19.20

Today's change-0.70 -3.52%
Updated April 28 4:00 PM -4GMT. Delayed by at least 15 minutes.

Coherus BioSciences Inc crosses below 20-day moving average

Coherus BioSciences Inc closed sharply lower Friday, dropping (U.S.)$0.70 or 3.52% to (U.S.)$19.20 and crossing below its 20-day moving average. Over the last five days, shares have gained 4.63%, but are down 31.79% for the last year to date. Shares have underperformed the S&P 500 by 15.12% during the last year.

Key company metrics

  • Open(U.S.) $19.90
  • Previous close(U.S.) $19.90
  • High(U.S.) $20.10
  • Low(U.S.) $19.05
  • Bid / Ask(U.S.) $0.00 / (U.S.) $21.65
  • YTD % change-31.79%
  • Volume434,626
  • Average volume (10-day)438,213
  • Average volume (1-month)431,445
  • Average volume (3-month)446,047
  • 52-week range(U.S.) $14.00 to (U.S.) $31.98
  • Beta--
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$3.48
Updated April 28 4:00 PM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-67.22%

Although this company's net profit margin is negative, it is above the industry average and implies that Coherus BioSciences Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.51%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2016Q3/2016Q2/2016Q1/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016
Revenue11631412
Total other revenue--------
Total revenue11631412
Gross profit--------
Total cost of revenue--------
Total operating expense74787777
Selling / general / administrative15141111
Research & development59656665
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-7385-63-64
Interest income (expense), net non-operating-2-2-2-1
Gain (loss) on sale of assets--------
Other--------
Income before tax-7684-70-66
Income after tax-7684-70-66
Income tax, total------0
Net income-7684-70-65
Total adjustments to net income--------
Net income before extra. items-7684-70-65
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-7684-70-65
Inc. avail. to common incl. extra. items-7684-70-65
Diluted net income-7684-70-65
Dilution adjustment--0----
Diluted weighted average shares44524139
Diluted EPS excluding extraordinary itemsvalue per share-1.711.63-1.72-1.67
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-1.711.63-1.72-1.67